JP2020510704A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510704A5
JP2020510704A5 JP2019571809A JP2019571809A JP2020510704A5 JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5 JP 2019571809 A JP2019571809 A JP 2019571809A JP 2019571809 A JP2019571809 A JP 2019571809A JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5
Authority
JP
Japan
Prior art keywords
cell
cancer
composition
composition according
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571809A
Other languages
English (en)
Japanese (ja)
Other versions
JP7277388B2 (ja
JP2020510704A (ja
Filing date
Publication date
Priority claimed from GBGB1704084.1A external-priority patent/GB201704084D0/en
Priority claimed from GBGB1721603.7A external-priority patent/GB201721603D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/050652 external-priority patent/WO2018167486A1/en
Publication of JP2020510704A publication Critical patent/JP2020510704A/ja
Publication of JP2020510704A5 publication Critical patent/JP2020510704A5/ja
Priority to JP2023076631A priority Critical patent/JP2023103318A/ja
Application granted granted Critical
Publication of JP7277388B2 publication Critical patent/JP7277388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571809A 2017-03-15 2018-03-14 方法 Active JP7277388B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076631A JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1704084.1 2017-03-15
GBGB1704084.1A GB201704084D0 (en) 2017-03-15 2017-03-15 Method
GBGB1721603.7A GB201721603D0 (en) 2017-12-21 2017-12-21 Method
GB1721603.7 2017-12-21
PCT/GB2018/050652 WO2018167486A1 (en) 2017-03-15 2018-03-14 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076631A Division JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Publications (3)

Publication Number Publication Date
JP2020510704A JP2020510704A (ja) 2020-04-09
JP2020510704A5 true JP2020510704A5 (https=) 2021-04-22
JP7277388B2 JP7277388B2 (ja) 2023-05-18

Family

ID=61868533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019571809A Active JP7277388B2 (ja) 2017-03-15 2018-03-14 方法
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Country Status (8)

Country Link
US (2) US11427645B2 (https=)
EP (1) EP3595705A1 (https=)
JP (2) JP7277388B2 (https=)
KR (2) KR102609624B1 (https=)
CN (1) CN110678197A (https=)
AU (2) AU2018235130B2 (https=)
CA (1) CA3056542A1 (https=)
WO (1) WO2018167486A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11126040B2 (en) 2012-09-30 2021-09-21 Optica Amuka (A.A.) Ltd. Electrically-tunable lenses and lens systems
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020028656A1 (en) * 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
WO2020076992A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
US20220325336A1 (en) * 2019-09-05 2022-10-13 Bluebird Bio, Inc. Transduction efficiency assay
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
IL296103A (en) * 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
EP4337227A2 (en) 2021-05-14 2024-03-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
KR20250090398A (ko) * 2022-09-28 2025-06-19 스팍스 바이오사이언스 리미티드 백혈구 면역글로불린 유사 수용체 하위 패밀리 b 구성원 2(lilrb2)에 결합하는 항체 및 그 용도
CN117069849B (zh) * 2023-03-21 2024-02-23 武汉奥科博泰生物科技有限公司 识别nag的单克隆抗体及其应用
CN117074674B (zh) * 2023-03-23 2024-01-23 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法
CN119074896A (zh) * 2024-10-11 2024-12-06 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) Il-12在制备治疗t-all的药物中的用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
JPH0813274B2 (ja) 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
EP1036091B2 (en) 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
GB9825303D0 (en) * 1998-11-18 1999-01-13 Oxford Biomedica Ltd Vector
GB9922361D0 (en) 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2002038612A2 (en) 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
EP1504108B1 (en) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviral vector
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
US7662625B2 (en) * 2002-07-02 2010-02-16 Cancer Research Technology Limited Methods for detecting the differentiation status of cells using 5T4 antigen expression
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
PE20100251A1 (es) 2004-09-10 2010-04-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
EP2045268B1 (en) 2005-05-13 2011-09-21 Oxford BioMedica (UK) Limited Mhc class I and II peptide antigens derived from tumour antigen 5t4
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
MY148763A (en) * 2006-03-10 2013-05-31 Wyeth Corp Anti-5t4 antibodies and uses thereof
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
WO2009070003A2 (en) 2007-11-30 2009-06-04 Mimos Berhad An analog read out interface circuit for ion sensor
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
EP2313784B1 (en) 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
EP2386062B1 (en) 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
ES2405605T3 (es) * 2009-03-27 2013-05-31 Wyeth Llc Células iniciadoras de tumores y procedimientos de uso de las mismas
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
GB201018480D0 (en) 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors
DK2694111T3 (en) * 2011-04-01 2016-10-10 Wyeth Llc Antibody pharmaceutical conjugates
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CA2927022C (en) * 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
ES2777305T5 (en) 2014-09-04 2025-09-30 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
JP6949728B2 (ja) 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
SG11202000503QA (en) * 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2020510704A5 (https=)
Zhang et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma
Alnefaie et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
Frank et al. Combining T-cell–specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors
Hou et al. Navigating CAR-T cells through the solid-tumour microenvironment
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
Ottaviano et al. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
Fan et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Abbott et al. To go or not to go? Biological logic gating engineered T cells
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
Spear et al. NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Pabst et al. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Pocock et al. Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia
Kim et al. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
Dinner et al. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Rosenzweig et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis
Zamagni et al. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Savani et al. New targets for CAR T therapy in hematologic malignancies
Kassner et al. Current landscape of CD3 bispecific antibodies in hematologic malignancies
Pratap et al. Finding new lanes: Chimeric antigen receptor (CAR) T‐cells for myeloid leukemia
Mehta et al. Monoclonal antibodies-based approaches in cancer immunotherapy
Sun et al. Macrophages: Targets for next-generation cancer immunotherapy
CN115850484A (zh) 一种靶向cd70的单链抗体及其应用
JPWO2020223702A5 (https=)
Baeuerle et al. T cell engagers emerge as a compelling therapeutic modality